DFC commits US $20 mn loan to Panacea Biotec towards capacity expansion for hexavalent vaccine
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Subscribe To Our Newsletter & Stay Updated